Takeda Pharmaceutical Co. $TAK Stake Boosted by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership grew its stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK) by 100.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,682,847 shares of the company’s stock after purchasing an additional 2,854,069 shares during the quarter. Arrowstreet Capital Limited Partnership’s holdings in Takeda Pharmaceutical were worth $88,596,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. Kestra Advisory Services LLC bought a new stake in Takeda Pharmaceutical in the 4th quarter valued at about $101,000. Parkside Financial Bank & Trust lifted its position in Takeda Pharmaceutical by 192.2% in the 4th quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock valued at $40,000 after purchasing an additional 1,684 shares during the last quarter. Stifel Financial Corp lifted its position in Takeda Pharmaceutical by 8.9% in the 4th quarter. Stifel Financial Corp now owns 554,290 shares of the company’s stock valued at $8,641,000 after purchasing an additional 45,366 shares during the last quarter. PCM Encore LLC bought a new stake in Takeda Pharmaceutical in the 4th quarter valued at about $1,182,000. Finally, Smartleaf Asset Management LLC lifted its position in Takeda Pharmaceutical by 24.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 24,772 shares of the company’s stock valued at $387,000 after purchasing an additional 4,877 shares during the last quarter. 9.17% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Sanford C. Bernstein upgraded shares of Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research report on Wednesday, April 8th. Wall Street Zen downgraded shares of Takeda Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 16th. Zacks Research upgraded shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 3rd. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Takeda Pharmaceutical in a research report on Wednesday, April 29th. Two analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy”.

Takeda Pharmaceutical Stock Down 1.0%

Takeda Pharmaceutical stock opened at $15.76 on Tuesday. The stock has a market cap of $50.14 billion, a price-to-earnings ratio of 40.40 and a beta of -0.07. The company has a current ratio of 1.27, a quick ratio of 0.70 and a debt-to-equity ratio of 0.56. The company’s 50-day moving average price is $16.66 and its two-hundred day moving average price is $16.73. Takeda Pharmaceutical Co. has a 52 week low of $12.99 and a 52 week high of $18.90.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Tuesday, March 31st. The company reported $0.56 EPS for the quarter. The firm had revenue of $6.90 billion for the quarter. Takeda Pharmaceutical had a net margin of 4.31% and a return on equity of 11.07%. On average, analysts expect that Takeda Pharmaceutical Co. will post 0.94 EPS for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.